FORT MYERS – October 31, 2026 -- Florida Cancer Specialists & Research Institute (FCS) President & Managing Physician Lucio N. Gordan, MD, will co-chair NCODA's inaugural Clinical Advances Summit (NCAS) in October 2027, with five FCS-linked leaders also named to NCODA's first Class of 2026 Fellows.
NCODA expands its conference format with a 2027 international summit
NCODA announced NCAS as the 2026 International Fall Summit drew to a close. The expanded meeting will bring together multidisciplinary and international oncology experts to address clinical innovations, research and emerging trends in cancer care. Gordan, who sits on NCODA's board of directors and executive council, will help shape the scientific direction of the event.
Gordan said "scientific progress reaches its full potential only when clinicians are prepared for what's ahead."
Five honorees join NCODA's inaugural Fellows class
NCODA introduced its Class of 2026 Fellows in recognition of long-standing leadership and service. The honorees named by FCS were:
- Lucio N. Gordan, MD
- Paul Chadwick, FCS chief procurement officer and NCODA Executive Council member
- Austin Cox, PharmD, FCS vice president of pharmacy services and NCODA Executive Council member
- Chris Elder, PharmD, BCOP, 2026 International Fall Summit Planning Committee member and 2024 recipient of NCODA's Living the Mission Award
- Ray Bailey, BPharm, RPH, retired FCS vice president of pharmacy services
FCS CEO Ryan Ciarrocchi said the recognition reflects the collective impact of the group and that FCS backs NCODA's plan to help oncology teams turn innovation into better care and outcomes.
FCS hosts the summit and fields two panels on 505(b)(2) products and team-based care
Gordan welcomed participants on behalf of FCS, the Host Practice for this year's flagship conference. Chadwick presented "Implementing 505(b)(2) Products at Scale in Community Oncology Network." Constance Rim, PharmD, BCOP, led "PQI in Action: Elevating Practice Through Team-Based Care."
FCS runs more than 180 active clinical trials each year through its research program with Sarah Cannon Research Institute (SCRI) and a set of independent site management programs.